Join to View Full Profile
1010 Main StBuffalo, NY 14202
Phone+1 716-323-0556
Fax+1 716-323-6674
Dr. Wolfe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemResidency, Neurology, 1990 - 1993- University of Pennsylvania Health SystemInternship, Internal Medicine, 1989 - 1990
University of Texas Southwestern Medical SchoolClass of 1989
Certifications & Licensure
NY State Medical License 2012 - 2027
CT State Medical License 2022 - 2025
TX State Medical License 1990 - 2025
PA State Medical License 1991 - 1994
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Clinical Neurophysiology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Awards, Honors, & Recognition
- Buffalo Spree Magazine Castle Connolly, 2013-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
- Super Doctor SuperDoctors.com
- Join now to see all
Clinical Trials
- Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Start of enrollment: 2006 Jun 01
- Efficacy of Prednisone In the Treatment of Ocular Myasthenia Start of enrollment: 2011 Dec 01
- International Guillain-Barré Syndrome Outcome Study Start of enrollment: 2012 May 01
Publications & Presentations
PubMed
- 1 citationsSafety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.Ali A Habib, Chongbo Zhao, Inmaculada Aban, Marcondes Cavalcante França Jr, Jorge Gustavo José
The Lancet. Neurology. 2025-02-01 - Myasthenia gravis: The evolving therapeutic landscape.Gil I Wolfe, Jonathan E Hanson, Nicholas J Silvestri
Eneurologicalsci. 2024-12-01 - 3 citationsRisk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis.A Gordon Smith, Gil I Wolfe, Ali A Habib, Cynthia Z Qi, Hongbo Yang
Advances in Therapy. 2024-12-01
Press Mentions
COVID-19 May Complicate Neuromuscular Conditions Such as MG, Review FindsAugust 7th, 2020
Pharmacy Times Continuing Education™ to Present Specialty Pharmacy CE Symposia in Washington, D.CAugust 28th, 2019
“Chemical Plasmapheresis” Drug for Myasthenia Gravis Is Safe, Lowers Antibodies, and Produces Hints of Efficacy in Phase 2 TrialJuly 11th, 2019- Join now to see all
Other Languages
- Hebrew
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
